gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Induction chemotherapy with paclitaxel and cisplatin, followed by accelerated-hyperfractionated radiotherapy in patients with advanced laryngeal and hypopharyngeal cancer – the DeLOS (Deutsche Larynxorganerhaltung-Studiengruppe)-trial

Meeting Abstract

  • corresponding author presenting/speaker Andreas Dietz - Strahlentherapie Universität Würzburg, Leipzig, Deutschland
  • Volker Rudat - Strahlentherapie UKE Hamburg
  • Florian Hoppe - HNO-Klinik Städt. Krankenhaus Oldenburg
  • Leo Pfreundner - Strahlentherapie Universität Würzburg
  • Michael Flentje - Strahlentherapie Universität Würzburg

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocOP239

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dkk2006/06dkk349.shtml

Veröffentlicht: 20. März 2006

© 2006 Dietz et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: Organ preservation with multimodality treatment in advanced laryngeal and hypopharyngeal cancer is coming up as an attractive alternative for total laryngectomy in Germany. A prospective multicenter phase II trial was performed to evaluate the effect of induction chemotherapy (ICHT) with paclitaxel/cisplatin followed by accelerated-hyperfarctionated (concomitant boost) radiotherapy (RT) in responders on larynx preservation, tumor control, survival and salvage surgery in patients with larynx/hypopharynx carcinoma eligible for total laryngectomy (TL) or TL plus partial pharyngectomy (TLPP).

Patients and Methods: 71 patients (40 larynx, 87,5% St.III,IV; 31 hypopharynx, 93,6% St. III,IV) eligible for TL or TLPP were enrolled onto a prospective multicenter study and treated with ICHT (200 mg/m(2) paclitaxel, 100 mg/m(2) cisplatin; day 1, 22) according to the DeLOS-protocol. Participating centers were the Universities of Würzburg, Hamburg, Heidelberg, Halle, Düsseldorf, Marburg, Tübingen, Köln, Homburg and medical centres of Kassel, Karlsruhe, Nordhausen. Patients with complete or partial tumor response proceeded to RT (69.9 Gy in 5.5 weeks). Non-responders received a TL/TLPP followed by postoperative RT (56-70 Gy in 51/2 to 7 weeks).

Results: The response rate to ICHT for larynx cancer was 70% (7,5% complete, 62,5% partial response) and for hypopharynx cancer was 84,3% (6,9% complete, 77,4 partial response). Overall survival after 24 months was 71,6% (95%-KI: 59.9% - 83.3%), laryngectomy-free survival after 24 months was 54.3% (95%-KI: 42.1% - 66.6%). Laryngectomy was indicated in 15 non-responders after ICHT. Five of the 15 non-responders refused the laryngectomy. Two of the five received RT instead and had no evidence of disease 2 years after RT. Late toxicity was tolerable (dysphagia III,IV lent soma: 1,8%) and salvage surgery without major complications.

Conclusion: In a large portion of patients eligible for TL or TLPP the larynx could be preserved after ICHT with paclitaxel/cisplatin followed by accelerated-hyperfractionated RT. Because of the relatively high proportion of non-responders after ICHT refusing the indicated laryngectomy, the role of ICHT to select patients for surgical or organ preservation therapy has to be questioned.